NCT00413075

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

Open Label, Dose Escalation Trial of Oral PXD101 in Patients With Advanced Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 121 (actual)
• Sponsor: Valerio Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will be given once or twice daily at various dosing schedules to patients with solid tumors. Doses will be escalated until the maximum tolerated dose (MTD) is identified. In parallel, a cohort of lymphoma patients will be given oral belinostat on a discontinuous once daily dosing schedule.

Conditions

• Solid Tumor
• Lymphoma

Interventions

Type	Name	Description
DRUG	oral belinostat	oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.

Timeline

• Start date: 2006-06-01
• Primary completion: 2011-08-01
• Completion: 2011-08-01
• First posted: 2006-12-19
• Last updated: 2015-07-08

Locations

6 sites across 3 countries: United States, Denmark, United Kingdom